22911-39-3

Basic information

• Product Name: 4-(Nitrooxy)butan-1-ol
• Synonyms: 4-(Nitrooxy)butan-1-ol;4-hydroxybutyl nitrate;4-NITROOXY-1-BUTANOL
• CAS NO: 22911-39-3
• Molecular Formula: C₄H₉NO₄
• Molecular Weight: 135.11856
• Mol File: 22911-39-3.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 216.039°C at 760 mmHg
• Flash Point: 84.458°C
• Appearance: /
• Density: 1.215g/cm³
• Vapor Pressure: 0.031mmHg at 25°C
• Refractive Index: 1.45
• PKA: 14.98±0.10(Predicted)
• CAS DataBase Reference: 4-(Nitrooxy)butan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Nitrooxy)butan-1-ol(22911-39-3)
• EPA Substance Registry System: 4-(Nitrooxy)butan-1-ol(22911-39-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 22911-39-3(Hazardous Substances Data)

Usage

General Description

4-(Nitrooxy)butan-1-ol, also known as nitroglycerin or glyceryl trinitrate, is a chemical compound commonly used as a medication for angina, heart failure, and high blood pressure. It is a nitrate ester that works by relaxing and dilating the blood vessels, allowing for increased blood flow to the heart and reducing the workload of the heart. This results in decreased chest pain and improved circulation. Nitroglycerin is available in various forms including tablets, ointments, and sprays, and is typically administered sublingually or transdermally. However, due to its potent vasodilatory effects, it must be used cautiously and under medical supervision to avoid potential side effects such as headaches, dizziness, and low blood pressure. Additionally, nitroglycerin is highly explosive and must be handled with extreme care.

InChI:InChI=1/C4H9NO4/c6-3-1-2-4-9-5(7)8/h6H,1-4H2

Upstream product

• 1141845-41-1 4-(nitrooxy)butyl 4-nitrobenzoate 
• 1141845-42-2 3-nitrobenzoic acid 4-nitryloxybutyl ester 
• 1100273-14-0 4-nitrooxybutan-1-ol butyrate 
• 907624-85-5 acetic acid 4-nitryloxybutyl ester 
• 110-63-4 Butane-1,4-diol 

Downstream Products

• 1538580-29-8 (Z)-4-(nitrooxy)butyl 2-(5-fluoro-2-methyl-1-(4-(methylthio)benzylidene)-1H-inden-3-yl)acetate 
• 1415910-90-5 4-(nitrooxy)butyl N-((benzyloxy)carbonyl)-2-[1-(3-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]-2-amino-acetate 
• 1415910-89-2 4-(nitrooxy)butyl N-((benzyloxy)carbonyl)-2-[1-(4-fluorophenyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]-1H-pyrrol-3-yl]-2-amino-acetate 
• 1415910-86-9 4-(nitrooxy)butyl N-(tert-butoxycarbonyl)-2-(1-(3-fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate 
• 1415910-85-8 4-(nitrooxy)butyl N-(tert-butoxycarbonyl)-2-(1-(4-fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)-1H-pyrrol-3-yl)-2-amino-acetate 
• 1346556-25-9 4-(nitrooxy)butyl N-[(4-methyl-5-thiazolyl)phenylmethyl]carbamate 
• 163133-43-5 naproxcinod 
• 1357362-70-9 2-formylphenyl (4-(nitrooxy) butyl) succinate 

Relevant articles and documents

Design, synthesis and biological activity evaluation of NO donor-containing ferrocene-pyrazole derivative

The invention discloses an NO donor-containing ferrocene-pyrazole derivative and a preparation method thereof. A structure of the NO donor-containing ferrocene-pyrazole derivative is shown by the following formula, wherein R is selected from the following groups.

Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy

A series of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy were designed, synthesized and biologically evaluated. Among them, compound 7l displayed the most potent inhibitory against COX-2 (IC50 = 0.82 μM) and antiproliferative activities against Hela cells (IC50 = 0.34 μM) compared with Celecoxib (IC50 = 0.38 and 7.91 μM). The further mechanistic studies revealed that 7l could induce apoptosis of Hela cells by mitochondrial depolarization and the antiproliferative activities of 7l were positively correlated with the levels of intracellular NO release in Hela cells. Most notably, 7l could dramatically suppress tumor growth in Hela cells xenografted mouse model. In summary, compound 7l may be promising candidates for cancer therapy.

QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS

The present invention relates to nitric oxide donor compounds having a quinone based structure of formula (I), wherein R1 to R6, m, n and p are as defined in claim 1, to processes for their preparation and to their use in the treatment of pathological conditions where a deficit of NO plays an important role in their pathogenesis, such as pulmonary arterial hypertension, Sickle cell disease, systemic sclerosis and scleroderma, muscular dystrophies, Duchenne's muscular dystrophy and Becker's muscular dystrophy, vascular dysfunctions.